(Adnkronos) - Nel nostro Paese sono circa 4,5 milioni le persone con il diabete di tipo, più del 90% dei casi di diabete diagnosticati sono rappresentati dalla forma di tipo 2, in aumento in tutto il mondo, Italia inclusa. Non solo, si stima che poco più di 1 paziente su 2 sia aderente alla cura suggerita. Una risposta concreta alle esigenze dei pazienti arriva da Aifa che ha approvato la rimborsabilità di tirzepatide di Lilly, il primo e fino ad oggi unico farmaco di una nuova classe terapeutica, agonista recettoriale di Gip e Glp-1. Il farmaco, inserito in Nota 100, può essere prescritto dagli specialisti e dai medici di Medicina generale. Un passo avanti nella terapia del diabete di tipo 2, con un miglioramento del profilo di cura, personalizzazione della terapia e minor ricorso a terapie più complesse e pronto soccorso. È quanto emerso oggi a Roma in occasione della conferenza stampa 'Diabete di tipo 2: investire in salute, tra accesso all'innovazione ed efficienza del Ssn, è la sfida per il futuro', promossa da Lilly.
00:00The Italian Pharmaceutical Agency has approved the reimbursement of Lily's tirzepatide, the first and until today the only drug of a new therapeutic class with a receptor of GIP GLP-1.
00:16The drug inserted in note 100 can be prescribed by specialists and by doctors of general medicine.
00:22It is the concrete answer to the needs of patients affected by diabetes and specialists arrived by the therapeutic innovation, as the diabetic disease is common, chronic, complex and expensive for those who cure and those who are cured.
00:3590% of cases diagnosed are represented by type 2 increase worldwide.
00:41The management of this disease is difficult and many patients' needs remain unsatisfied.
00:47Only one out of two people with type 2 diabetes, in fact, reaches the pre-set target of 6.57% of hemoglobin glycated, reference parameter, which indicates if the diabetes over time is well compensated.
01:01This is often linked to a delayed diagnosis, to the non-tempestuous use of drugs that can modify the natural history of the disease, but also to the difficulty of management in everyday life by the person, which translates into reduced adherence to the use of drugs.
01:18Therefore, new therapeutic opportunities are welcome, which are able to significantly impact on all these aspects and therefore allow us to cure this pathology, which has a strong clinical impact on the quality of life, but also on the sustainability of our national health system.
01:37Diabetes, as a chronic disease, involves an increased risk of complications of the vascular nature, which involve several organs.
01:46This is why in the management of patients it is important to adopt a multidisciplinary approach.
01:51The commitment must be that, not only to ensure, obviously, competent specialists in this specific territory, which is that of diabetology, therefore an oculist who knows the complications of diabetes,
02:03but the problem is to make sure that the specialist reaches and sees the patient at the right time, not too late, when the complications are already advanced and this is an organizational issue, not always so simple to deal with and solve.
02:21Lilia has always been a protagonist in the fight against diabetes, thanks to a constant commitment to research and development of innovative therapy, a commitment that today is renewed with Tirzahepatid.
02:32A product completely made in Italy, we are proud to produce it in our plant in Sesto Fiorentino, through an expansion that has guaranteed an investment in Italy of about 1 billion euros.
02:45A product that is exported to more than 70 countries around the world, a product that today is available in all regions of Italy and the shelves from Sesto Fiorentino started with the Italian flag,
02:58therefore a double reason for pride for us as a company, but above all a great opportunity for patients and for the system as a whole.
Be the first to comment